Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

DEA's PROPOSED 1985 AGGREGATE PRODUCTION QUOTA FOR CODEINE (FOR SALE) is 54.05 mil. grams, according to figures published in the Oct. 11 Federal Register. The codeine aggregate production level proposed by the Drug Enforcement Administration (DEA) is 3.0% above the 52.5 mil. gram level approved by DEA in 1984. The agency proposed a decrease, from 3.58 mil. to 3.53 mil. in the aggregate production quota for codeine (for conversion). In the notice, DEA published its proposals for production quotas for Schedule I and Schedule II controlled substances. The agency recommended quota increases for 14 of 35 agents (for list of proposed 1985 production quotas and 1984 quotas, see box below). (FOOTNOTE) Other substances for which DEA proposed increases, include: morphine (for conversion), a 4.7% increase to 58.08 mil. grams; thebaine, up 14.2% to 6.89 mil. grams; morphine (for sale), up 8.8% to 1.14 mil. grams; methadone, up 31.7% to 1.38 mil. grams; and methadone intermediate, up 31.7% to 1.38 mil. grams. The agency explained that in proposing the quotas, it took account of five factors: (1) actual disposals for 1983 and estimates for 1984 and 1985 for each mfr.; (2) projected trends in net disposals; (3) inventory estimates; (4) projected demand; (5) "estimates of change in legitimate medical needs"; (6) "documented diversion." The deadline for comments on the proposed quotas is Nov. 13. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts